Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

HYLORIS PHARMACEUTICALS SA

(HYL)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur HYLORIS PHARMACEUTICALS SA
03/01JAARUITGELICHT : Hyloris schittert op de beurs in 2021
2021KBC Securities verhoogt koersdoel Hyloris
2021Hyloris Partners With Vaneltix Pharma to Develop, Commercialize Interstitial Cystitis P..
2021Hyloris tekent samenwerking met Vaneltix
2021Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in ..
2021Hyloris Enters into Strategic Partnership with Vaneltix for Treatment of Acute Pain in ..
2021KBC trekt Brussel in het rood
2021Brussel verder in het rood
2021KBC zet Bel20 lager
2021Bel20 start week lager
2021US FDA to Decide on Approval of Hyloris Painkiller Earlier Than Expected
2021FDA zal eerder dan verwacht Maxigesic van Hyloris evalueren
2021Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic® IV
2021Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic? IV
2021Hyloris Starts Strategic Partnership With Pleco Therapeutics
2021Hyloris tekent samenwerking met Pleco Therapeutics
2021Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute My..
2021Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute My..
2021Pleco Therapeutics B.V. announced that it expects to receive ?1 million in funding from..
2021Hyloris behandelt eerste patient in Fase 2 studie
2021Hyloris Pharmaceuticals Kicks Off Mid-Stage Trial of Vulvovaginal Candidiasis Treatment
2021Hyloris Announces Start of Phase 2 Study of Miconazole-Domiphen Bromide Vaginal Cream i..
2021Hyloris Pharmaceuticals SA Announces Start of Phase 2 Study of Miconazole-Domiphen Brom..
2021FDA accepteert aanvraag pijnstiller Hyloris
2021Hyloris Post-Operative Pain Treatment's New Drug Application Gets US FDA Acceptance
2021Hyloris Announces FDA Acceptance of New Drug Application for Maxigesic® IV in Post-Oper..
2021Hyloris Pharmaceuticals SA Announces FDA Acceptance of New Drug Application for Maxiges..
2021HYLORIS PHARMACEUTICALS' : Post-Operative Pain Treatment Gets Regulatory Approvals in UK, ..
2021Groen licht voor Hyloris in VK en Ierland
2021HYLORIS PHARMACEUTICALS : Announces Approval of Maxigesic® IV in the UK and Ireland
2021Hyloris Announces Approval of Maxigesic® IV in the UK and Ireland
2021Galapagos houdt Bel20 in het groen
2021Recticel uitblinker op lichtgroene beurs
2021HYLORIS PHARMACEUTICALS : Secures Licensing Deal for Rhoshan's Intravenous Acetylsalicylic..
2021Hyloris verwerft technologie van Rhoshan Pharmaceuticals
2021HYLORIS PHARMACEUTICALS : Acquires Breakthrough, Patented Technology to Develop and Market..
2021Hyloris Pharmaceuticals SA Enters into an Exclusive, Worldwide Licensing Agreement with..
2021Bel20 sluit lichtjes in het rood
2021Brussel blijft terughoudend
2021HYLORIS PHARMACEUTICALS : Acquires Global Rights to Heart Failure Drug
2021KBC Securities verhoogt koersdoel Hyloris
2021Hyloris breidt pijplijn uit
2021HYLORIS PHARMACEUTICALS : Expands Cardiovascular Pipeline with Breakthrough Extended-Relea..
2021Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Ca..
2021Hyloris Pharmaceuticals SA acquired Global Rights to CRD-102 from Baker Heart and Diabe..
2021HYLORIS PHARMACEUTICALS : Appoints New CFO From Bone Therapeutics
2021Hyloris stelt Jean-Luc Vandebroek aan als CFO
2021HYLORIS PHARMACEUTICALS : Appoints Jean-Luc Vandebroek as Chief Financial Officer
2021Hyloris Pharmaceuticals SA Appoints Jean-Luc Vandebroek as its Chief Financial Officer
2021HYLORIS PHARMACEUTICALS' : Post-Operative Pain Drug Wins OK in South Korea, Panama
2021Vlakke start Bel20 verwacht na laat herstel Wall Street
2021Maxigesic van Hyloris krijgt goedkeuring in Zuid-Korea
2021HYLORIS PHARMACEUTICALS : Announces Further Extension of Maxigesic® IV Footprint
2021Hyloris Pharmaceuticals SA Announces Further Extension of Maxigesic® Iv Footprint
2021Geen grote verrassingen bij Hyloris
2021Positieve start Bel20 verwacht
2021Omzetexplosie voor Hyloris
2021Hyloris Pharmaceuticals Sa Reports Earnings Results for the Second Quarter Ended June 3..
2021Hyloris Pharmaceuticals SA Reports Consolidated Earnings Results for the Half Year Ende..
2021HYLORIS PHARMACEUTICALS : to Report 2021 Half-Year Results on 4 August 2021
2021HYLORIS PHARMACEUTICALS : Starts Selling Non-Opioid Painkiller in Germany, Austria
2021Hyloris lanceert pijnstiller Maxigesic op Duitse markt
2021Hyloris Pharmaceuticals Sa Launches Maxigesic IV
2021Certain Subscription Rights of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agre..
2021Certain Warrants of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Endin..
2021Hyloris heronderhandelt met succes over licentieovereenkomsten
2021Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter P..
2021Brussel verder omhoog
2021Biotech helpt Bel20 omhoog
2021Jaarvergadering Hyloris keurt alle agendapunten goed
2021Berenberg verhoogt koersdoel Hyloris
2021HYLORIS PHARMACEUTICALS : Extends Maxigesic IV Licensing Deal to 17 Latin American Countri..
2021Hyloris-partner breidt licentieovereenkomst Maxigesic uit
2021Hyloris Announces Extension of Footprint of Maxigesic® IV into South America
2021Hyloris presenteert Amerikaanse partner
1  2Suiv.
Prochain événement sur HYLORIS PHARMACEUTICALS SA